Base to Base biotech podcast 71: The IgA/CD89 axis

This week, we have a conversation Paweł Szczepański, CEO of JJP Biologics about specially-built antibodies to tackle autoimmune diseases and cancer.JJP BiologicsJJP Biologics is a clinical-stage biotech that leverages its in-depth understanding of immune pathway science in autoimmune diseases and cancer. Starting from deep mechanistic insights, JJPBio engineers antibodies that are built-to-order, designed to restore immune balance and deliver better disease control for patients with significant unmet need, because we believe that we can do better for patients.JJPBio is the first company to generate clinical validation of the IgA/CD89 axis, establishing first-mover advantage in a disease area with broad implications across autoimmune conditions including IgA nephropathy, rheumatoid arthritis, lupus, and celiac disease. Its immuno-oncology programme targets the CD270/HVEM checkpoint pathway in cancer.Backed by the long-term, socially responsible capital of the Starak family and the Polpharma Group, JJPBio operates with the scientific freedom and financial stability to pursue mechanisms others simply cannot.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]